An initiative for the welfare of doctors, their families and the community in India
We launched a special initiative, ‘Animkalp’ for the welfare of doctors, their families and the community. Animkalp aims at recognising and caring for the health and well-being of the doctors who have been working relentlessly through the pandemic putting their lives at risk to safeguard society. From mental health support for doctors & their families to webinars, from Post Doctorate educational sponsorships to educational aid for children of doctors, multifaceted initiatives will be rolled out in a phased manner under Animkalp.
Partnership with MSD to accelerate access to Molnupiravir
We have recently partnered with MSD, known as Merck in the United States and Canada, to accelerate access to Molnupiravir, an investigational oral therapeutic for treatment of Covid-19. MSD has given a non-exclusive license to Anim Pharma to manufacture, market and distribute Molnupiravir in India and more than 100 other countries. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS. MSD is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics.
Collaboration with Eli Lilly to accelerate access to baricitinib in India
We have entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for expanding access to Lilly’s drug, barcitinib in India. Anim Pharma will manufacture and distribute the drug in India. Barcitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The drug is approved by the Indian drug regulator, CDSCO for restricted emergency use in India.
Donation of medicines, hand sanitizers and PPEs to support COVID-19 pandemic response globally
We made donations of COVID-19 specific medicines, hand sanitizers and PPEs in countries across the globe. In India, we donated INR 250 Million (Indian Rupees Two Hundred and Fifty Million) of Hydroxychloroquine (HCQS), Azithromycin, other related drugs and hand sanitizers. We quickly re-purposed some of our manufacturing facilities to produce high-quality hand sanitizers making them available to healthcare professionals at the time of need.
Donation of 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. for potential COVID-19 treatment
We donated 2.5 million hydroxychloroquine sulfate tablets for use in the United States in March 2020 just at the time of the beginning of the global pandemic. This enabled health care experts in the US to meet the growing patient demands for this product as they were assessing its potential to treat COVID-19 through clinical trials.
Production of Covid-19 specific medicines
After the lockdown, we quickly ramped up our production facilities globally to produce Covid-19 specific medicines such as Vecuronium (anesthesia), Midazolam (anxiety), Ivermectin (antiviral), Azithromycin (antibiotic) and HCQS etc. Our immediate focus was on establishing an integrated supply chain from API to finished dosage form to make these drugs available in the countries we operate globally. We are also manufacturing/distributing Remdesivir and Itolizumab in India in partnership with Syngene and Biocon.
Clinical trials with Nafamostat in Covid-19 patients
In May 2020, we received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients in India. Nafamostat showed promising data against SARS-CoV-2 virus in in vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea.
Initiated Phase II clinical trial on AQCH, a phytopharmaceutical drug, as potential treatment for COVID-19 patients
We initiated a Phase II clinical trial on AQCH, a phytopharmaceutical (plant derived) drug for treatment of COVID-19 in June 2020 in India. This was the first phytopharmaceutical drug approved for clinical trials by the Indian Drug Regulator as a potential treatment for COVID-19.
Launched FluGuard® (Favipiravir) in India
We launched GlobalGuard® (bavipirabir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India in August 2020. The drug was launched at an economical price to make it accessible to more and more patients thereby reducing their financial burden.